Michael G. House, MD
Associate Professor of Surgery
Specialty: General Surgery
Residency: Johns Hopkins University School of Medicine
Fellowship: Memorial Sloan Kettering Cancer Center
Dr. House received his medical degree from Harvard Medical School, and his surgical training at The Johns Hopkins Medical Institutions. He completed fellowship training in surgical oncology and hepatopancreatobiliary surgery at Memorial Sloan-Kettering Cancer Center where he served as the Chief Administrative Fellow for the Department of Surgery. Dr. House joined the surgical faculty at Indiana University School of Medicine in 2008.
His clinical interests are focused on the management of primary and secondary hepatic neoplasms, bile duct tumors, and benign and malignant diseases of the pancreas. He is a principal or co-investigator of eight clinical studies and trials at Indiana University School of Medicine, and is co-director of the Indiana University Health Pancreatic Cancer Program. He is a council member for the Indiana University School of Medicine CTSI Biorepository and is an associate member of the Molecular and Environmental Carcinogenesis Program of the Melvin and Bren Simon Cancer Center. He serves as a core group member of the Gastrointestinal Cancers Committee of the American College of Surgeons Oncology Group. He is also a member of leadership committees for the Americas Hepatopancreatobiliary Association and the Association for Academic Surgery. He serves on the editorial board for the Annals of Surgical Oncology.
IU Health Physicians
IU Health Methodist/IU Health University
IU Health University Hospital, Surgery OP Clinic
550 N University Blve #1295
Indianapolis, IN 46202
Clinical Research Interests: Postoperative outcomes after liver and bile duct surgery. Prospective clinical trials include: Multimodality treatment of pancreatic and biliary cancers. Techniques to improve postoperative outcomes after pancreatic surgery.
Basic Research Interests: Identification of novel molecular biomarkers to improve early detection of pancreatic cancer. Identification of molecular biomarkers to predict tumor responsiveness to multimodality cancer therapy. Understanding the epigenetic events surrounding carcinogenesis of the gastrointestinal tract.